MLAB
Market read
No new filing conclusion is available. 0 of 25 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 0 directly disclosed connections are confirming.
Invalidation: The isolated read changes if MLAB's group or a disclosed connection begins moving with it.
Research brief
No new filing conclusion is available. 0 of 25 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 0 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
No credible peer-relative valuation comparison is available yet.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“2024 Interest expense and amortization of debt issuance costs $ 10,692 $ 11,859 $ 5,697 (9.8 %) 108.2 % (Gain) on extinguishment of convertible senior notes - (2,887 ) - (100.0 %) N/A Other (income) expense, net (4,195 ) 1,403 (2,124 ) (399.0 %) (166.1 %) Non…”10-K · Jun 3, 2026 ↗
“Our Clinical Genomics division experienced revenue declines, primarily due to unfavorable macroeconomic conditions in China and ongoing trade tensions, which have weakened demand for our Clinical Genomics products and services in that region.”10-K · Jun 3, 2026 ↗
“2024 Revenues $ 45,386 $ 47,081 $ 52,588 (3.6 %) (10.5 %) Gross profit 26,028 25,670 27,078 1.4 % (5.2 %) Gross profit as a % of revenues 57.3 % 54.5 % 51.5 % 2.8 pt 3.0 pt Clinical Genomics revenues decreased 3.6% in fiscal year 2026 compared to fiscal year…”10-K · Jun 3, 2026 ↗
“2024 Revenues $ 45,386 $ 47,081 $ 52,588 (3.6 %) (10.5 %) Gross profit 26,028 25,670 27,078 1.4 % (5.2 %) Gross profit as a % of revenues 57.3 % 54.5 % 51.5 % 2.8 pt 3.0 pt Clinical Genomics revenues decreased 3.6% in fiscal year 2026 compared to fiscal year…”10-K · Jun 3, 2026 ↗
Valuation discipline
Price/sales 2.7× · EV/sales 2.9×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:35 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for MLAB. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
Jodie has not yet found a suitable current-versus-prior filing comparison for MLAB. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
MLAB is currently a Early Follower in the organic co-movement group Financial Services & Tech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. No verified filing-linked names are available yet.
This group is retained as the last observed read for MLAB; it is not active in the latest market snapshot.
Context history
No durable theme membership has been observed for this name yet.